All News
EULAR 2022 – Day 3 Report
By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
Read Article
#EULAR2022 LB0001
Bimekizumab (IL-17F and IL-17A) in bionaive PsA
BE OPTIMAL phase 3 trial, 24 weeks
⭐️Met Primary endpt - ACR50
⭐️Met other ACR and PASI endpts
⭐️Safety: higher fungal infections
@RheumNow https://t.co/x8u6B93FNl
Eric Dein ericdeinmd ( View Tweet)
Fascinating! Richette et al. Machine learning identifies 8 clusters of PsA phenotypes. Treatment responses seem to differ, being better in cluster 2 and worse in cluster 5 and 6 (at least for IL23i guselkumab). @RheumNow #EULAR2022 POS1055 https://t.co/QIh2SbJKpa
Richard Conway RichardPAConway ( View Tweet)
Magrey et al. IL23i Risankizumab improves enthesitis in PsA @RheumNow #EULAR2022 POS1057 https://t.co/BjuYj6xUdZ
Richard Conway RichardPAConway ( View Tweet)
BE OPTIMAL Phase 3 RCT
Bimekizumab dual IL17A & F inhibitor in bionaive PsA
⭐️ACR50 wk 16 43.9% vs 10% PBO
⭐️PASI 90 wk 16 61% vs. 3% PBO
⭐️separation from wk 4
Safety: fungal injections BKZ > ADA
@RheumNow
LB0001 #EULAR2022 https://t.co/7ZwV1XDSNb
Aurelie Najm AurelieRheumo ( View Tweet)
Dr Coates @DrLauraCoates et al. Domains contributing to MDA achievement in guselkumab treated PsA. Physican assessed improved faster than patient assessed. Age, fatigue, BMI, baseline domain score determinants @RheumNow #EULAR2022 POS1067 https://t.co/vPsmeyPjzG
Richard Conway RichardPAConway ( View Tweet)
High markers at baseline of IL23 pathway better predict ACR20 response to #deucracitinib in #PsA #psoriatic arthritis. Analysis of RCT @eular_org @RheumNow #POS0005 Good proof of concept of TYK2 efficacy https://t.co/yyH5niUEEU
Janet Pope Janetbirdope ( View Tweet)
CorEvitas PsA Registry (1000+ pts)
Analysis of biologics prescription according to disease domains
No real surprise to see that IL-17i were prescribed more frequently in pts w/ PsO BSA>10% at BL
Overall first line TNFi 40% > IL-17i 14%
POS0309 @RheumNow #EULAR2022 https://t.co/dkLxl8d6ug
Aurelie Najm AurelieRheumo ( View Tweet)
The two forms of Axial PsA - classical (Axial SpA like) and alternative. Plenary session today #EULAR2022 by Prof. Philip Helliwell. I will be discussing this further in my vlog @RheumNow https://t.co/hxAhgMhHlJ
Dr. Antoni Chan synovialjoints ( View Tweet)
Kristensen et al. IL23i Risankizumab improves fatigue, health related quality of life, work productivity in PsA. @RheumNow #EULAR2022 POS1042 https://t.co/fnoCZCpwNM
Richard Conway RichardPAConway ( View Tweet)
Nash @drpnash et al. IL23i guselkumab improves pain in PsA. Good to see as it is a really important PRO, but there is still significant work to do, week 24 - 60% had <50% and 37% had <20% improvement in pain @RheumNow #EULAR2022 POS1044 https://t.co/H92r4leslT
Richard Conway RichardPAConway ( View Tweet)
Mulder et al. COMPLETE-PsA trial. MTX+LEF vs MTX mono. 78 patient RCT. LEF 20mg, MTX 25mg. MTX+LEF more effective (MDA 59% vs 32%) but less well tolerated (3 SAE vs 0; N+V, diarrhoea. No mention of LFTs). @RheumNow #EULAR2022 POS0078 https://t.co/2D84EFmabc
Richard Conway RichardPAConway ( View Tweet)
So what diet to follow with autoimmunity in mind?
So many, all with different instructions.
Let’s concentrate on where they agree:
yes to fruits & vegetables
no to emulsifiers & processed foods
#EULAR2022 @RheumNow https://t.co/I9abweQOyZ
David Liew drdavidliew ( View Tweet)
Mease et al. IL23i guselkumab on axial outcomes in PsA at 2 years in DISCOVER-2. Guselkumab improves BASDAI, mBASDAI, spinal pain, ASDAS to week 100. Still trying to get my head around this seeming to work for PsA spinal disease but not axSpA @RheumNow #EULAR2022 POS1037 https://t.co/LZgXEl6Ohl
Richard Conway RichardPAConway ( View Tweet)
Does diet drive IL-23 in IBD and PsA? Perhaps if you have the right baseline risk. The science is evolving quickly
Stronger rationale that diet may be really important in some patients
#EULAR2022 #IL23 @RheumNow https://t.co/hV54PvfOXV
David Liew drdavidliew ( View Tweet)
Incidentally looked at the FLORA study in @RheumNow Tuesday Night Rheumatology for ‘PsA All The Way’, a month before #EULAR2022
https://t.co/s5qa4breCf
https://t.co/a52myvJMMc
David Liew drdavidliew ( View Tweet)
Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IMPROVED over biologic era. To me, suggests benefits of proper disease control on infection risk
@RheumNow
#EULAR2022 OP0274 https://t.co/cqUoRti4We https://t.co/Ozz7jH3z4N
Links:
Richard Conway RichardPAConway ( View Tweet)
LDA/MDA achieved in 60% of PsA pts on (mostly) bDMARDs. Combo baseline features: TJC>3, SJC>5, CRP>10 mg/l, HAQ>0.5, enthesitis, dactylitis, BMI>30 & sDMARDs tx constitutes negative predictive impact on MDA/LDA after 1 yr. #EULAR2022 POS0080 @RheumNow https://t.co/PugwiuSMPm https://t.co/nqadEjA3Xe
Dr. Rachel Tate uptoTate ( View Tweet)
Izokibep - potent and small molecule IL-17A inhibitor Phase 2 study in PsA patients
Fast onset, met ACR50 primary endpoint
AE included site reaction and candida infection
@RheumNow #EULAR2022 ABST#OP0258 https://t.co/vZ4xmnhyhl
Robert B Chao, MD doctorRBC ( View Tweet)
Add on MTX does not impair UST immunogenicity in PsA. #EULAR2022 POS0079 @RheumNow
https://t.co/CalEn7KpsX https://t.co/NZUqdX0XKo
Dr. Rachel Tate uptoTate ( View Tweet)
